Stay updated on Lenvatinib Plus Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Lenvatinib Plus Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the Lenvatinib Plus Pembrolizumab in Melanoma Clinical Trial page
- Check5 days agoChange DetectedThe page now displays Revision: v3.5.4 in place of Revision: v3.5.3, indicating a new site software release. This update affects page labeling but not the underlying study information.SummaryDifference0.0%

- Check12 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedThis updates the page’s revision/version label from **v3.5.2** to **v3.5.3** in the footer, indicating a minor site maintenance change rather than a change to the underlying trial information.SummaryDifference0.0%

- Check34 days agoChange DetectedAdded revision: v3.5.2. Removed revision: v3.5.0.SummaryDifference0.0%

- Check63 days agoChange Detected- Revision: v3.5.0 added. The previous Revision: v3.4.3 was removed.SummaryDifference0.0%

- Check77 days agoChange DetectedPage revision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check99 days agoChange DetectedFooter revision updated from v3.4.1 to v3.4.2. No changes to study details, eligibility criteria, outcomes, or participating locations.SummaryDifference0.0%

Stay in the know with updates to Lenvatinib Plus Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lenvatinib Plus Pembrolizumab in Melanoma Clinical Trial page.